

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	10165-037-999	10/520,140
	APPLICANT	
	Brines et al.	
	FILING DATE	ART UNIT
	January 3, 2005	1647

U.S. PATENT DOCUMENTS					
*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
/CMW/	A13 60/458,193	3/28/2003	Renzi		
	A14 09/290,938	4/13/1999	Brines et al		
	A15 09/547,220	4/11/2000	Brines et al.		
	A16 09/716,963	11/21/2000	Brines et al.		
	A17 09/718,829	11/21/2000	Brines et al.		
	A18 11/880,275	7/19/2007	Brines et al.		
	A19 2002/0052309	5/02/2002	Anagnostou et al.		
	A20 2002/0061849	5/23/2002	Nielsen et al.		
	A21 2002/0081734	6/27/2002	Choi et al.		
	A22 2002/0160460	10/31/2002	Paulson et al.		
	A23 2003/0003529	1/2/2003	Bayer		
	A24 2003/0040037	2/27/2003	Bayer		
	A25 2003/0072737	4/17/2003	Brines et al.		
	A26 2003/0089468	5/15/2003	Kettunen et al.		
	A27 2003/0104988	6/5/2003	Brines et al.		
	A28 2003/0120045	6/26/2003	Bailon		
	A29 2003/0134798	7/17/2003	Brines et al.		
	A30 2004/0009902	1/15/2004	Boime		
	A31 2004/0091961	5/13/2004	Evans et al.		
	A32 2004/0122216	6/24/2004	Nielsen et al.		
	A33 2004/0209812	10/21/2004	Farrell et al.		
	A34 2004/0214236	10/28/2004	Brines et al.		
	A35 2005/0106722	5/19/2005	Jones et al.		
	A36 2005/0164386	7/28/2005	Uytdchraig et al.		
	A37 2005/0170463	8/04/2005	Bout et al.		
	A38 2005/0176627	8/11/2005	Cerami et al.		
	A39 2006/0099685	5/11/2006	Yallop et al.		
	A40 2006/0216757	9/28/2006	Brines et al.		
/CMW/	A41 2007/0054394	3/08/2007	Bout et al.		

<b>EXAMINER</b> NYI-4228197v1	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO.
	10165-037-999	10/520,140
	APPLICANT	
	Brines et al.	
	FILING DATE	ART UNIT
	January 3, 2005	1647

U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	
/CMW/	A42 2007/0117742	5/24/2007	Opstelten et al.		
	A43 2007/0129293	6/07/2007	Coleman et al.		
	A44 2007/0231860	10/04/2007	Uytdehaag et al.		
	A45 2007/0275439	11/29/2007	Opstelten		
	A46 2007/0298031	12/27/2007	Brines et al.		
	A47 2007/0298464	12/27/2007	Optelten et al.		
	A48 2008/0014193	1/17/2008	Brines et al.		
	A49 2008/0032922	2/07/2008	Opstelten et al.		
	A50 2008/0050403	2/28/2008	Marzio et al.		
	A51 2008/0305990	12/11/2008	Brines et al.		
	A52 2009/0004202	1/01/2009	Brines et al.		
	A53 2009/0136519	5/28/2009	Brines et al.		
	A54 2009/0233844	9/17/2009	Brines et al.		
	A55 2009/0258821	10/15/2009	Cerami et al.		
	A56 4,343,782	8/10/1982	Shapiro		
	A57 4,992,419	2/12/1991	Woog et al.		
	A58 5,278,065	6/11/1994	D'Andrea		
	A59 5,292,654	3/08/1994	Yoshimura		
	A60 5,354,934	10/11/1994	Pitt et al.		
	A61 5,591,713	1/07/1997	Igari et al.		
	A62 5,604,198	2/18/1997	Poduslo et al.		
	A63 5,750,376	5/12/1998	Weiss et al.		
	A64 5,763,198	6/09/1998	Hirth et al		
	A65 5,824,672	10/20/1998	Simpkins et al.		
	A66 5,997,865	12/7/1999	Bennett et al.		
	A67 6,048,971	4/11/2000	Sytkowski et al.		
	A68 6,071,970	6/06/2000	Mueller et al.		
	A69 6,103,526	04/15/2005	Smith et al.		
/CMW/	A70 6,121,246	9/19/2000	Isner		

EXAMINER NY14228(97v1)	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO	APPLICATION NO
	10165-037-999	10/520,140
	APPLICANT	
	Brines et al.	
	FILING DATE	ART UNIT
	January 3, 2005	1647

U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL /CMW/	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
A71	6,153,407	11/28/2000	Sytkowski et al.	
A72	6,200,567	3/13/2001	Lopez et al.	
A73	6,242,570	6/05/2001	Sytkowski	
A74	6,291,661	09/18/2001	Graddis et al.	
A75	6,340,742	1/22/2002	Burg et al.	
A76	6,399,336	6/4/2002	Paulson et al.	
A77	6,440,932	8/27/2002	Lehmann et al.	
A78	6,475,717	11/05/2002	Enssle et al.	
A79	6,489,293	12/3/2002	Sytkowski et al.	
A80	6,521,245	2/18/2003	Zaharia	
A81	6,583,272	6/24/2003	Bailon	
A82	6,645,522	11/11/2003	Naeff et al.	
A83	6,784,154	8/31/2004	Westenfelder	
A84	6,855,544	2/15/2005	Hateboer et al.	
A85	6,930,086	8/16/2005	Tischer	
A86	7,053,184	5/30/2006	Lee	
A87	7,087,224	8/8/2006	Kay et al.	
A88	7,091,326	8/15/2006	Lee et al.	
A89	7,098,318	8/29/2006	Lee et al.	
A90	7,214,532	5/08/2007	Stern et al.	
A91	7,220,555	5/22/2007	Paulson et al.	
A92	7,262,166	8/28/2007	Kinstler et al.	
A93	7,297,680	11/20/2007	Opstelten et al.	
A94	7,300,915	11/27/2007	Campana et al.	
A95	7,300,916	11/27/2007	Yasuda et al.	
A96	7,304,031	12/04/2007	Opstelten et al.	
A97	7,309,687	12/18/07	Brines et al.	
A98	7,345,019	3/18/08	Brines et al.	
/CMW/	A99	8/12/08	Brines et al.	

EXAMINER NYI-4228197v1	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with <b>MPER 609</b> ; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY DOCKET NO	APPLICATION NO
	10165-037-999	10/520,140
	APPLICANT	
	Brines et al.	

FILING DATE January 3, 2005	ART UNIT 1647
--------------------------------	------------------

### U.S. PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
/CMW/	A100 7,504,248	3/17/2009	Marzio et al.	
	A101 6,747,002	6/8/2004	Cheung et al.	

### FOREIGN PATENT DOCUMENTS

	FOREIGN PATENT DOCUMENT NUMBER, COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
/CMW/	B14 CA 2,294,448	12/30/1998	Roche Diagnostics Gmbh		
	B15 DE 198 57 609	6/15/00	Ehrenreich and Gleiter (w/English abstract)		
	B16 EP 0640619	1/3/1995	Amgen Inc.		
	B17 EP 0668351	8/23/1995	Amgen, Inc.		
	B18 EP 0883343	4/24/1997	St. Elizabeth's Medical Center of Boston, Inc.		
	B19 EP 1064951	1/03/2001	F. Hoffmann-La Roche AG		
	B20 EP 1440157	5/8/2003	Crucell Holland B.V.		
	B21 EP 1625858	2/15/2006	St. Elizabeth's Medical Center of Boston, Inc.		
	B22 EP 1633383	3/15/2006	Janssen Pharmaceutica N.V.		
	B23 EP 1831381	7/6/2006	Crucell Holland B.V.		
	B24 EP 1889627	2/20/2008	Niigata TLO Corporation		
	B25 FR 2 823 220	10/11/2002	Genodyssee (w/English abstract)		
	B26 JP-05092928	4/16/93	Snow Brand Milk Prod Co., Ltd., (w/English abstract)		
	B27 WO 1985/002610	6/20/1985	Kirin-Amgen, Inc.		
	B28 WO 1986/003520	6/19/1986	Genetics Institute, Inc.		
	B29 WO 1990/011354	10/4/1990	Institut Pasteur (w/English abstract)		
	B30 WO 1991/005867	5/2/1991	Amgen Inc.		
	B31 WO 1991/006667	5/16/1991	Cell Genesys, Inc.		
	B32 WO 1991/009955	7/11/1991	Applied Research Systems, ARS Holding MV		
	B33 WO 1993/009222	5/13/1993	Transkaryotic Therapies, Inc.		
/CMW/	B34 WO 1993/025221	12/23/1993	Alkermes Controlled Therapeutics		

EXAMINER NYI-4228197V1	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO. <b>10165-037-999</b>	APPLICATION NO. <b>10/520,140</b>
APPLICANT <b>Brines et al.</b>			
FILING DATE <b>January 3, 2005</b>		ART UNIT <b>1647</b>	

FOREIGN PATENT DOCUMENTS						
		FOREIGN PATENT DOCUMENT COUNTRY CODE NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR,	T
/CMW/	B35	WO 1994/012650	6/9/1994	Transkaryotic Therapies, Inc.		
	B36	WO 1995/005465	2/23/1995	Amgen Inc.		
	B37	WO 1995/031560	11/23/1995	Transkaryotic Therapies, Inc.		
	B38	WO 1997/008307	3/6/1997	Il Dong Pharmaceutical Co. Ltd.		
	B39	WO 1997/014307	4/24/1997	St. Elizabeth's Medical Center of Boston, Inc.		
	B40	WO 1998/010650	3/19/1998	East Carolina University		
	B41	WO 1998/058660	12/30/1998	Boehringer Mannheim GMBH (w/English abstract)		
	B42	WO 1999/021966	5/06/1999	Neurospheres Holdings Ltd.		
	B43	WO 2000/024893	5/4/2000	Amgen, Inc.		
	B44	WO 2000/032772	6/8/2000	Eli Lilly & Co.		
	B45	WO 2000/061164	10/19/00	Kenneth S. Warren Laboratories		
	B46	WO 2001/002017	1/11/2001	F. Hoffmann-La Roche AG		
	B47	WO 2001/081405	11/1/2001	Amgen Inc.		
	B48	WO 2001/087329	11/22/2001	F. Hoffmann-La Roche AG		
	B49	WO 2002/000721	1/3/2002	ZymoGenetics, Inc.		
	B50	WO 2002/014356	2/21/2002	Althoff, Claudia		
	B51	WO 2002/049673	6/27/2002	F. Hoffmann-La Roche AG		
	B52	WO 2002/053580	7/11/02	Kenneth S. Warren Institute, Inc.		
	B53	WO 2003/029291	4/10/2003	F. Hoffmann-La Roche AG		
	B54	WO 2003/038100	5/8/2003	Crucell Holland B.V.		
	B55	WO 2003/089468	10/30/2003	Crucell Holland B.V.		
	B56	WO 2004/003176	1/8/04	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B57	WO 2004/004656	1/15/04	The Kenneth S. Warren Institute, Inc.		
	B58	WO 2004/022577	3/18/2004	Warren Pharmaceuticals, Inc.; Kenneth S. Warren Institute, Inc.		
	B59	WO 2004/087063	10/14/2004	Janssen Pharmaceutica NV		
	B60	WO 2004/096148	11/11/04	The Kenneth S. Warren Institute, Inc.		
	B61	WO 2004/112693	12/29/2004	Kenneth S. Warren Institute, Inc.		
/CMW/	B62	WO 2005/025606	3/24/05	Warren Pharmaceuticals, Inc.;		

EXAMINER NYI-422819751	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO <b>10165-037-999</b>	APPLICATION NO <b>10/520,140</b>
		<b>APPLICANT</b> <b>Brines et al.</b>	
		FILING DATE <b>January 3, 2005</b>	ART UNIT <b>1647</b>

**FOREIGN PATENT DOCUMENTS**

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
/CMW/	B63	WO 2005/032467	4/14/05	Kenneth S. Warren Institute, Inc.		
	B64	WO 2005/084364	9/15/05	Warren Pharmaceuticals, Inc.		
	B65	WO 2005/117927	12/15/05	The Kenneth S. Warren Institute, Inc.		
	B66	WO 2006/002646	1/12/06	The Kenneth S. Warren Institute, Inc. and H. Lundbeck A/S		
	B67	WO 2006/014349	2/9/06	H. Lundbeck A/S		
	B68	WO 2006/014466	2/9/06	The Kenneth S. Warren Institute, Inc., et al.		
	B69	WO 2006/070011	7/6/2006	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S		
	B70	WO 2006/129755	12/7/2006	Crucell Holland B.V.		
/CMW/	B71	WO 1994/028024	12/8/1994	Niigata TLO Corporation (w/English Abstract)		
				Enzon, Inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
/CMW/	C118	Patent Interference No. 105,500 Ehrenreich v. Brines; Judgment Paper I, Declaration, Brines clean copy of claims, and Ehrenreich clean copy of claims (10/02/06)	
	C119	ABDELRAHMAN, 2004, "Erythropoietin attenuates the tissue injury associated with hemorrhagic shock an myocardial ischemia," Shock, Vol. 22 (1), pp 63-69	
	C120	AGNELLO et al., 2002, "Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis," Brain Research 952:128-134	
	C121	AKHTAR et al., 1999, "Conformational study of N(epsilon)-(carboxymethyl)lysine adducts of recombinant alpha-crystallins," Current Eye Research 18:270-276	
	C122	ALAFACI et al., 2000, "Effect of Recombinant Human Erythropoietin on Cerebral Ischemia Following Experimental Subarachnoid Hemorrhage," Eur. J. Phar., 406:219-225.	
	C123	ANAGNOSTOU et al., 1994, "Erythropoietin receptor mRNA expression in human endothelial cells", Proc. Natl. Acad. Sci. USA 91:3974-3978	
	C124	ANDO et al., 1996, "Autonomic dysfunction and anemia in neurologic disorders", J. Autonomic Nervous Syst. 61:145-148	
	C125	ANNABLE et al., 1972, "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay," Bull. Org. Mond. Santé, 47:99-112.	
	C126	ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAF, 2004, "Empfehlungen zur Therapie der Demenz," Arzneiverordnung in der Praxis, Band 31, Sonderheft 4 (w/English abstract)	
/CMW/	C127	ASHWELL et al., 1978, "A Protein from Mammalian Liver that Specifically Binds Galactose-Terminated Glycoproteins," Meth. Enzymol., 50:287-291.	

EXAMINER NYI-4228197v1	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO. <b>10165-037-999</b>	APPLICATION NO <b>10/520,140</b>
APPLICANT <b>Brines et al.</b>			
	FILING DATE <b>January 3, 2005</b>	ART UNIT <b>1647</b>	

/CMW/	C128	AY et al., 1999, "Potential usefulness of basic fibroblast growth factor as a treatment for stroke," <i>Cerebrovascular Disease</i> 9:131-135	
	C129	BANY-MOHAMMED et al., 1996, "Recombinant human erythropoietin: possible role as an antioxidant in premature rabbits," <i>Pediatric Res.</i> 40(3):381-387	
	C130	BARBER et al., 2001, "De novo design of cytokine-based alpha helical binding domains display cytotoxic activity," <i>Blood</i> 98(11, part 2):132b-133b Abstract 4193	
	C131	BARBER et al., 1994, "Erythropoietin and interleukin-2 activate distinct JAK kinase family members," <i>Mol. Cell. Biol.</i> 14(10):6506-6514	
	C132	BARBONE et al., 1997, "Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships," <i>J. Biol. Chem.</i> 272(8):4985-4992	
	C133	BARRON et al., 1994, "Alternatively spliced mRNAs encoding soluble isoforms of the erythropoietin receptor in murine cell lines and bone marrow," <i>Gene</i> 147:263-8	
	C134	BASKAYA et al., 1997, "The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats," <i>Neuroscience Lett.</i> 226:33-36	
	C135	BAZAN, 1989, "A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain," <i>Biochem. Biophys. Res. Commun.</i> 164(2):788-795	
	C136	BELAYEV et al., 1996, "Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats," <i>Brain Research</i> 739:88-96	
	C137	BENIT et al., 1993, "The 'WS motif' common to v-mpl and members of the cytokine receptor superfamily is dispensable for myeloproliferative leukemia virus pathogenicity," <i>Oncogene</i> 8:787-790	
	C138	BENYO et al., 1999, "Expression of erythropoietin receptor by trophoblast cells in the human placenta," <i>Biol. Reprod.</i> 60:861-870	
	C139	BERNAT et al., 2003, "Determination of the energetics governing the regulatory step in growth hormone-induced receptor homodimerization," <i>PNAS</i> Vol. 100(3):952-57	
	C140	BERNAUDIN et al., 2000, "Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain," <i>Glia</i> 30:271-278	
	C141	BESARAB et al., 1998, "The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin," <i>New England Journal of Medicine</i> 339(9):584-590	
	C142	BIANCHI et al., 2004, "Erythropoietin both protects from and reverses experimental diabetic neuropathy," <i>PNAS</i> , Vol. 101, pp. 823-828	
	C143	BICKEL et al., 1993, "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," <i>Proc Natl Acad Sci USA</i> 90:2618-22	
	C144	BICKEL et al., 1994, " <i>In vivo</i> demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium," <i>J Histochem Cytochem.</i> Vol. 42(11):1493-7	
	C145	BOADO et al., 1998, "Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS," <i>J Pharm Sci.</i> Vol. 87(11):1308-15.	
	C146	BOGER and GOLDBERG, 2001, "Cytokine receptor dimerization and activation: prospects for small molecule agonists," <i>Bioorg. &amp; Med. Chem.</i> , 9:557-562	
	C147	BOGOYEVITCH, 2004, "An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection," <i>Cardiovascular Research</i> , Vol. 63, pp. 208-16	
↓	C148	BOISSEL et al., 1993 "Erythropoietin structure-function relationships," <i>J. Biol. Chem.</i> Vol. 268(21):15983-15993	
/CMW/	C149	BONSI et al., 1997, "An erythroid and megakaryocytic common precursor cell line (B1647) expressing both c-mpl and erythropoietin receptor (Epo-R) proliferates and modifies globin chain synthesis in response to megakaryocyte growth and development factor (MGDF) but not to erythropoietin (Epo)," <i>Br. J. Haematol.</i> 98:549-559	

EXAMINER NYI-4228197v1	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO 10165-037-999	APPLICATION NO 10/520,140
APPLICANT Brines et al.		FILING DATE January 3, 2005	ART UNIT 1647
/CMW/	C150	BOUDOT et al., 1999, "Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2)," <i>J. Biol. Chem.</i> 274(48):33966-33972	
	C151	BRIGGS et al., 1974, "Hepatic Clearance of Intact and Desialylated Erythropoietin," <i>Am. J. Physiol.</i> 227(6):1385-1388.	
	C152	BRINES et al., 2004, "Erythropoietin mediates tissue protection through an erythropoietin and common $\beta$ -subunit heteroreceptor," <i>PNAS</i> , Vol. 101(41):14907-14912	
	C153	BRIZZI et al., 1991, "Hematopoietic growth factor receptors," <i>Int. J. Cell. Cloning</i> 9:274-300	
	C154	BRUNEVAL et al., 1993, "Erythropoietin Synthesis by Tumor Cells in a Case of Meningioma Associated With Erythrocytosis," <i>Blood</i> , 81(6):1593-1597.	
	C155	BUEMI et al., 2002, "Recombinant human erythropoietin influences revascularization and healing in a rat model of random ischaemic flaps," <i>Acta Derm. Venereol.</i> 82:411-417	
	C156	BUNDGAARD and MOLLER, 1981, "Horseradish peroxidase and microperoxidase. Their purity and binding to serum proteins," <i>J. Histochem. Cytochem.</i> 29(3):331-336	
	C157	CALVILLO et al., 2003, "Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling," <i>Proc. Nat. Acad. Sci. USA</i> 100:4802-6	
	C158	CAMISCOL et al., 1968, "Comparative Assay of Erythropoietin Standards," <i>Annals New York Acad. Sci.</i> , 149:40-45.	
	C159	CARAVELLA et al., 1996, "A partial model of the erythropoietin receptor complex," <i>Proteins</i> 24:394-401	
	C160	CARDIN et al., 2003, "Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways," <i>Cardiovasc Res.</i> 60(2): 315-325	
	C161	CERNEUS and VAN DER ENDE, 1991, "Apical and basolateral transferrin receptors in polarized BeWo cells recycle through separate endosomes," <i>J. Cell Biol.</i> 114(6):1149-1158.	
	C162	CHIN et al., 2000, "Production and processing of erythropoietin receptor transcripts in brain," <i>Mol. Brain Res.</i> 81: 29-42	
	C163	CLAUS-WALKER et al., 1984, "Spinal Cord Injury and Serum Erythropoietin," <i>Arch. Phys. Med. Rehabil.</i> , 65:370-374.	
	C164	COTES et al., 1961, "Bio-Assay of Erythropoietin in Mice Made Polycythaemic By Exposure to Air at a Reduced Pressure," <i>Nature</i> , 191:1065-1067.	
	C165	COTES et al., 1966, "The International Reference Preparation of Erythropoietin," <i>Bill. Org. mond. Sante</i> , 35:751-760.	
	C166	COTES, 1968, "Quantitative Estimation of Erythropoietin," Part I. Assay and Standardization of Erythropoietin, <i>Annals New York Acad. Sci.</i> , 149:12-17.	
	C167	CUNNINGHAM and WELLS, 1989, "High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis," <i>Science</i> 244:1081-1085	
	C168	D'ANDREA and GONDA, 2000, "A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit," <i>Exp. Hematol.</i> 28(3):231-243	
	C169	D'ANDREA et al., 1998, "Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice," <i>J. Clin. Invest.</i> 102(11):1951-1960	
	C170	D'ANDREA and ZON, 1990, "Erythropoietin receptor. Subunit structure and activation," <i>J. Clin. Invest.</i> 86(3):681-687	
↓	C171	DALE et al., 2002, "Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface," <i>Nature</i> 415:175-179	
/CMW/	C172	DAME et al., 2001, "The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential," <i>Biol. Neonate</i> 79(304):228-235	

EXAMINER  
NYI-4228197v1

DATE CONSIDERED

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY DOCKET NO. 10165-037-999	APPLICATION NO 10/520,140
APPLICANT Brines et al.	
FILING DATE January 3, 2005	ART UNIT 1647

/CMW/	C173	DEGUCHI et al., 1999, "Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker," <i>Bioconjug Chem.</i> 10(1):32-37	
	C174	DEL MASTRO and VENTURI, 1998, "Strategies for the use of epoetin alfa in breast cancer patients," <i>The Oncologist</i> , 3:314-318	
	C175	DENIZOT and LANG, 1986, "Rapid colorimetric assay for cell growth and survival – Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability," <i>J. Immunol. Meth.</i> 89:271-277	
	C176	DIAZ-BRINTON and YAMAZAKI, 1998, "Advances and challenges in the prevention and treatment of Alzheimer's disease," <i>Pharm. Res.</i> 15(3):386-98	
	C177	DIETRICII et al., 1993, "Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats," <i>J. Neuropathol. Experimental Neurol.</i> , 52(4):351-360	
	C178	DISPERSYN et al., 1999, Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation: prelude to apoptosis, <i>Cardiovasc. Res.</i> , 43(4): 947-957	
	C179	DOBBIN et al., 1989, "Transient blood-brain barrier permeability following profound temporary global ischaemia. An experimental study using <sup>14</sup> C-AIB," <i>J. of Cerebral Blood Flow Metabolism</i> 9:71-78	
	C180	DONG et al., 1992, "Receptor binding of asialoerythropoietin," <i>J. Cell. Biochem.</i> 48(3):269-276	
	C181	DORDAL et al., 1985, "The Role of Carbohydrate in Erythropoietin Action," <i>Endocrinol.</i> , 116(6):2293-2299,	
	C182	DOX et al., 1993, "The Harper Collins Illustrated Medical Dictionary," Harper Collins Publishers, Inc. New York, 1993	
	C183	DUBE et al., 1988, "Glycosylation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function," <i>J. Biol. Chem.</i> , 263(33):17516-17521.	
	C184	ECKART, 2002, "Anaemia of critical illness—implications for understanding and treating rHuEPO resistance," <i>Nephrol Dial Transplant</i> 17, Suppl 5, pp. 48-55	
	C185	EGRIE and BROWNE, 2001, "Development and characterization of novel erythropoiesis stimulating protein (NESP)," <i>Nephrol. Dial. Transplant</i> 16 (suppl. 3):3-13	
	C186	EHRENREICH, 2004, "Erythropoietin: a candidate compound for neuroprotection in schizophrenia," <i>Molecular Psychiatry</i> , 9:42-54	
	C187	EHRENREICH, 2004 "A boost for translational neuroscience," <i>Science</i> , Vol. 305:184-185	
	C188	ELLIOTT et al., 1997, "Mapping of the active site of recombinant human erythropoietin," <i>Blood</i> 89(2):493-502	
	C189	EMIR, 2004, "Erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury," <i>Transplantation Proceedings</i> , Vol. 36, pp. 2935-2938	
	C190	ERBAYRAKTAR et al., 2003, "Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 100(11):6741-6	
	C191	EUR. PHARMACOPOEIA, 1997, Sainte-Ruffine, France, Maisonneuve p. 5.	
	C192	EUR. PHARMACOPOEIA, Strasbourg, Council of Europe, Suppl. 2001, pp. 777-782.	
	C193	FARRELL et al., 2001, "Erythropoietin crosses the blood brain barrier", <i>Blood</i> 98:148b (abstr. # 4265; 43rd Annual Meeting of the American Society of Hematology, Orlando FL, Dec. 7-11, 2001)	
	C194	FARUKI and KISS, 1995, "Erythropoietin, transfusion medicine update, The Institute for Transfusion Medicine, path.upmc.edu/consult/ria/july 1995.html	
	C195	FEIGIN et al., 2002, "Recent advances in Huntington's disease: implications for experimental therapeutics," <i>Curr. Opin. Neurol.</i> 15(4):483-489	
↓	C196	FISHBEIN et al., 1981, "Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique," <i>Am. Heart Journal</i> 101(5): 593-600	
/CMW/	C197	FORESTA et al., 1994, "Erythropoietin stimulates testosterone production in man," <i>J. Clin. Endocrinol. Metabol.</i> 78(3):753-756	

EXAMINER  
NYI-12281971

DATE CONSIDERED

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO. <b>10165-037-999</b>	APPLICATION NO <b>10/520,140</b>
APPLICANT <b>Brines et al.</b>			
FILING DATE <b>January 3, 2005</b>	ART UNIT <b>1647</b>		

/CMW/	C198	FRANK, 2002, "Minireview: Receptor dimerization in GH and erythropoietin action--it takes two to tango, but how?" <i>Endocrinology</i> 143(1):2-10	
	C199	FRESHNEY, 1983, "Culture of animal cells," A Manual of Basic Technique, A.R. Liss, Inc., NY 1983, pp. 3-4	
	C200	FRIDEN, 1996, "Utilization of an endogenous cellular transport system for the delivery of therapeutics across the blood-brain barrier," <i>J. Controlled Release</i> 46:117-28	
	C201	FRIEDMAN et al., 1995, "Erythropoietin in diabetic macular edema and renal insufficiency," <i>Am. J. Kidney Disease</i> 26(1), pp. 202-208	
	C202	FUKUDA et al., 1989, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates," <i>Blood</i> , 73(1):84-89.	
	C203	FUJITA et al., 1997, "Role of alternative splicing of the rat erythropoietin receptor gene in normal and erythroleukemia cells," <i>Leukemia</i> , 11 (Suppl. 3): 444-445	
	C204	FUNG and GREENE, 1990, "The human interleukin-2 receptor: insights into subunit structure and growth signal transduction," <i>Semin. Immunol.</i> 2:119-128	
	C205	GABRIEL et al., 1998, "High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome," <i>J. Trauma</i> 44(2):361-367	
	C206	GAERTNER et al., 1994, "Chemo-enzymic backbone engineering of proteins," <i>J. Biol. Chem.</i> 269(10):7224-7230	
	C207	GARCIA et al., 1996, "Ischemic stroke and incomplete infarction," <i>Stroke</i> , Vol. 27(4):761-765	
	C208	GARTHOFF, 1995, "Safety and Efficacy Testing of Hormones and Related Products," The Report and Recommendations of ECVAM Workshop 9, A.T.L.A., 23:699-711	
	C209	GENBANK No. M59941, 1994 (Human GM-CSF Receptor $\beta$ chain)	
	C210	GOLDBERG et al., 2002, "Erythropoietin mimetics derived from solution phase combinatorial libraries," <i>J. Amer. Chem. Soc.</i> 124(4):544-555	
	C211	GOLDWASSER et al., 1975, "Erythropoietin: Assay and Study of Its Mode of Action," <i>Methods in Enzymology, Hormone Action Part B, Peptides Hormones</i> , 1975 Academic Press, Vol. 28, pp. 109-121.	
	C212	GOLDWASSER et al., 1974, "On the Mechanism of Erythropoietin-Induced Differentiation," XIII. The Role of Sialic Acid in Erythropoietin Action, <i>J. Biol. Chem.</i> , 249(13):4202-4206.	
	C213	GOLDWASSER et al., 1975, "An Assay for Erythropoietin <i>In Vitro</i> at the Millilitr Level," <i>Endo.</i> , 97(2):315-323.	
	C214	GRASSO et al., 2006, "Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietin erythropoietin derivative," <i>J. Neurosurg. Spine</i> 4(4):310-318	
	C215	GREEN, 1998, "Clomethiazole (Zendral®) in acute ischemic stroke: Basic pharmacology and biochemistry and clinical efficacy," <i>Pharmacol Ther.</i> 80(2):123-147	
	C216	GREENBERG et al. 1995, "Congestive heart failure and sleep apnoea-possible mechanisms and effect of CPAP therapy," <i>J. Sleep Res.</i> 4(S1): 130-134	
	C217	GREGORY et al., 1999, "GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-x <sub>L</sub> expression," <i>Blood</i> 94:87-96	
	C218	GRIMM et al., 2002, "HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration," <i>Nature Medicine</i> 8(7):718-724	
	C219	GROTHZINGER, 2002, "Molecular mechanisms of cytokine receptor activation," <i>Biochim. Biophys. Acta</i> , 1592:215-223	
	C220	GRUBER et al., 2002, "The thrombin mutant W215A/E217A shows safe and potent anticoagulant and anti-thrombotic effects <i>in vivo</i> ," <i>J. Biol. Chem.</i> 277(31):27581-27584	
▼	C221	GUNASEKAR et al., 2001, "Mechanisms of the apoptotic and necrotic actions of trimethyltin in cerebellar granule cells," <i>Toxicological Sciences</i> 64:83-89	
/CMW/	C222	HAMMOND et al., 1968, "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. II. Aplastic Crisis. III. Erythropoietic Effects of Normal Plasma," <i>Annals NY Academy of Sciences</i> 149:516-527.	

EXAMINER NY-422819751	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO.
10165-037-999	10/520,140
APPLICANT	
Brines et al.	
FILING DATE	ART UNIT
January 3, 2005	1647

/CMW/	C223	HANAZONO et al., 1995, "Erythropoietin induces tyrosine phosphorylation of the beta chain of the GM-CSF receptor," <i>Biochem. Biophys. Res. Comm.</i> 208(3):1060-1066
	C224	HANCHER et al., 1974, "Recovery of Erythropoietin from Anemic Sheep Plasma," <i>Biootechnology and Bioengineering</i> 16:1069-1079
	C225	HANSSEN et al., 2000, "A randomized, blinded placebo controlled, phase II, dose-finding study of ARANESP in patients with lymphoproliferative malignancies," <i>Blood</i> , Vol. 96(11), pp. 155b, Abstr. 4371
	C226	HARRIS et al., 1992, "Ligand binding properties of the human erythropoietin receptor extracellular domain expressed in <i>Escherichia coli</i> ," <i>J. Biol. Chem.</i> 267(21):15205-15209
	C227	HARRIS et al., 2000, "Purification and characterization of yeast-expressed erythropoietin (R103A), an erythropoietin antagonist," <i>Blood</i> 96(11, part 2):154b Abstract 4366
	C228	HARRIS et al., 2001, "Characterization of the yeast-expressed erythropoietin mutant, Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis," <i>Blood</i> , 98(11, part 1):77a Abstract 319
	C229	HARRIS K. W., 2004, "Signal transduction in myeloid differentiation," <i>Federal Research in Progress database, FRP 03-05, ID No. 136456, Comp &amp; Dist. By NTIS</i>
	C230	HASSAN and FREUND, 1995, "Review of megakaryoblastic leukaemia cell lines -Characteristic biological features of human megakaryoblastic leukaemia cell lines," <i>Leuk. Res.</i> 19(9):589-594
	C231	HÖRKÖ et al., 1992, "Carbamylation-induced alterations in low-density lipoprotein metabolism," <i>Kidney Int.</i> 41(5):1175-1181
	C232	HORTON et al., 1991, "Von Hippel-Lindau Disease and Erythrocytosis: Radioimmunoassay of Erythropoietin in Cyst Fluid From a Brainstem Hemangioblastoma," <i>Neurology</i> , 41:753-754.
	C233	HUWYLER and PARDRIDGE, 1998, "Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries," <i>J. Neurochem.</i> 70(2):883-886
	C234	HUWYLER et al., 1997, "Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat," <i>J Pharmacol Exp Ther.</i> 282(3):1541-1546.
	C235	IMADA et al., 1992, "Interleukin-2 (IL-2) induces erythroid differentiation and tyrosine phosphorylation in EML-I-1 cells transfected with a human IL-2 receptor beta chain cDNA," <i>Biochem. Biophys. Res. Commun.</i> 188(1):352-357
	C236	IMAI et al., 1990, "Physicochemical and Biological Characterization of Asialoerythropoietin," <i>Eur. J. Biochem.</i> , 194:457-462.
	C237	ISEKI et al., 1996, "Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients," <i>Nephron</i> 72:30-36
	C238	ITOH et al., 1990, "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family," <i>Science</i> 247:324-327
	C239	JACOBS et al., 1985, "Isolation and characterization of genomic and cDNA clones of human erythropoietin," <i>Nature</i> 313(28):806-810
	C240	JENKINS et al., 1999, "A cell type-specific constitutive point mutant of the common β-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor α-subunit for activation," <i>J. Biol. Chem.</i> 274(13):8669-8677
	C241	JIANG et al., 1996, "Delayed intravenous administration of basic fibroblast growth factor (bFGF) reduces infarct volume in a model of focal cerebral ischemia/reperfusion in the rat," <i>J. Neurological Sciences</i> 139:173-179
	C242	JONES et al., 1990, "Human erythropoietin receptor: cloning, expression, and biologic characterization," <i>Blood</i> 76(1):31-35
	C243	JOOSS et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," <i>Hum. Gene Ther.</i> 7(13):1555-1566
/CMW/	C244	JOSSE et al., 1999, "Human serum paraoxonase (PON1): Identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis," <i>Chem. Biol. Interact.</i> 119-120:71-78

**EXAMINER**  
 NYI-4228197v1
**DATE CONSIDERED**

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY DOCKET NO	APPLICATION NO
10165-037-999	10/520,140
APPLICANT	
Brines et al.	
FILING DATE	ART UNIT
January 3, 2005	1647

/CMW/	C245	JOSSE et al., 1999, "Tryptophan residue(s) as major components of the human serum paraoxonase active site," <i>Chem. Biol. Interact.</i> 119-120:79-84	
	C246	JUBINSKY et al., 1996, "The $\beta$ c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and $\beta$ -globin mRNA expression," <i>Mol. Med.</i> 2(6):766-773	
	C247	JUBINSKY et al., 1997, "The $\beta$ chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor," <i>Blood</i> 90(5):1867-1873	
	C248	JUUL et al., 1998, "Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus," <i>Early Human Dev.</i> 52(3):235-249	
	C249	JUUL et al., 2001, "Recombinant erythropoietin (EPO) crosses the blood brain barrier (BBB) in preterm fetal sheep," <i>Soc. for Neuroscience Abstracts</i> 27(1):929 (31st Annual Meeting of the Society for Neuroscience, San Diego, CA Nov. 10-15, 2001)	
	C250	JUUL, S. 2002, "Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage," <i>Acta Paediatr. Supp.</i> 438:36-42	
	C251	KANG et al., 1994, "Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor," <i>Drug Metab. Dispos.</i> 22(1):99-105	
	C252	KAWASAKI et al., 2001, "Structural analysis of sulfated N-linked oligosaccharides in erythropoietin," <i>Glycobiology</i> 11(12):1043-1049	
	C253	KAYE DM et al., 2003, Feasibility and short-term efficacy of percutaneous mitral annular reduction for the therapy of heart failure-induced mitral regurgitation. <i>Circulation</i> 108:1795-1797	
	C254	KEIGHLEY, 1968, "Further Experiences with Assays, Units, and Standards of Erythropoietin," <i>Annals New York Acad. Sci.</i> 149:18-24.	
	C255	KESWANI et al., 2004, "A novel endogenous erythropoietin mediated pathway prevents axonal degeneration," <i>Ann. Neurol.</i> Vol. 56(6):815-826	
	C256	KIRITO et al., 2002, "Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation," <i>Blood</i> 99(1):102-110	
	C257	KISHIMOTO and TAVASSOLI, 1987, "Transendothelial transport (transcytosis) of iron-transferrin complex in the rat liver," <i>Am. J. Anat.</i> 178:241-249.	
	C258	KITAMURA et al., 1989, "Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1," <i>Blood</i> 73(2):375-80	
	C259	KOHAMA et al., 2000, "Large Uterine Myoma with Erythropoietin Messenger RNA and Erythrocytosis," <i>Obstetrics and Gynecology</i> , 96(5):826-828.	
	C260	KRAFT-E-JACOBS et al., 1996, "Circulating erythropoietin and interleukin-6 concentrations increase in critically ill children with sepsis and septic shock," <i>Crit. Care Med.</i> 24(9):1455-1459	
	C261	KUMRAL et al., 2004, "Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rat," <i>Behavioral Brain Research</i> , Vol. 153:77-86	
	C262	KUROIWA et al., 1985, "The biphasic opening of the blood-brain barrier to proteins following temporary middle cerebral artery occlusion," <i>Acta Neurochirurgica</i> 68:122-129	
	C263	LAI et al., 1996, "The molecular role of the common gamma $\epsilon$ subunit in signal transduction reveals functional asymmetry within multimeric cytokine receptor complexes," <i>Proc. Natl. Acad. Sci. USA</i> 93:231-235	
	C264	LEE et al., 1998, "Conditional lineage ablation to model human diseases," <i>Proc. Natl. Acad. Sci. USA</i> 95:11371-11376	
	C265	LEITGEB et al., 1994, "Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin," <i>Cancer</i> , 73(10):2535-2542	
	C266	LEIST et al., 2004, "Derivatives of erythropoietin that are tissue protective but not erythropoietic," <i>Science</i> , Vol. 305, pp. 239-242	
/CMW/	C267	LEWIS et al., 1996, "Molecular characterization of the 7q deletion in myeloid disorders," <i>Br. J. Haematol.</i> 93:75-80	

EXAMINER  
NYI-4228197v1

DATE CONSIDERED

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY DOCKET NO	APPLICATION NO
10165-037-999	10/520,140
APPLICANT	
Brines et al.	
FILING DATE	ART UNIT
January 3, 2005	1647

/CMW/	C268	LEWIS et al., 2004, "Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation <i>in vitro</i> ," <i>Exp. Hematol.</i> 32:36-44	
	C269	Li et al., 1996, "Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses", <i>Pediatr. Res.</i> 40(3):376-380	
	C270	LINSLEY et al., 1994, "Applications of electrospray mass spectrometry to erythropoietin N- and O-linked glycans," <i>Anal. Biochem.</i> 219:207-217	
	C271	LIU et al., 1994, "Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc." <i>Mol. Cell. Biol.</i> 14(10):6926-6935	
	C272	LIU et al., 1996, "Transgenic mice containing the human erythropoietin receptor gene exhibit correct hematopoietic and neural expression," <i>Proc. Assoc. Am. Physicians</i> 108(6):449-454	
	C273	LIVNAH et al., 1999, "Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation," <i>Science</i> 283:987-990	
	C274	LOBERG et al., 1993, "Neuronal uptake of plasma proteins after transient cerebral ischemia/hypoxia," <i>APMIS</i> 101:777-783	
	C275	LOWY et al., 1960, "Inactivation of Erythropoietin by Neuraminidase and by Mild Substitution Reactions," <i>Nature</i> , 185:102-103.	
	C276	LU et al., 2005, "Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury," <i>J. of Neurotrauma</i> , Vol. 22(9), pp. 1011-1017	
	C277	MAGNANTI et al., 2001, "Erythropoietin expression in primary rat Sertoli and peritubular myoid cells," <i>Blood</i> 98(9):2872-2874	
	C278	MAITANI et al., 1996, "Oral administration of recombinant human erythropoietin in liposomes in rats: influence of lipid composition and size of liposomes on bioavailability," <i>J. Pharm. Sci.</i> 85(4):440-45	
	C279	MASSAGUE, 1987, "The TGF-beta family of growth and differentiation factors," <i>Cell</i> 49:437-438	
	C280	MATSUYAMA et al., 2000, "Erythrocytosis Caused by an Erythropoietin-Producing Hepatocellular Carcinoma," <i>J. Surg. Oncology</i> , 75:197-202.	
	C281	MATTHEWS et al., 1996, "A sequential dimerization mechanism for erythropoietin receptor activation," <i>Proc. Natl. Acad. Sci. USA</i> 93:9471-9476	
	C282	MCCLURE et al., 2001, "GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit," <i>Cytokine</i> 13(4):240-243	
	C283	MEANS and KRANTZ, 1996, "Inhibition of human erythroid colony-forming units by interferons $\alpha$ and $\beta$ : differing mechanisms despite shared receptor," <i>Exp. Hematol.</i> 24:204-208	
	C284	MENZIES and ELLIS, 1990 "Intestinal obstruction from adhesions - how big is the problem?", <i>Ann. R. Coll. Surg. Engl.</i> 72:60-63	
	C285	MENZIES et al., 1990, "Extravasation of albumin in ischaemia brain oedema," <i>Acta Neurochirurgica, Suppl.</i> 51:220-222	
	C286	MIONI et al., 1992, "Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells," <i>Acta Endocrinologica</i> 127:459-465	
	C287	MIIU et al., 2004, "Have no fear, erythropoietin is here, erythropoietin protects fear conditioning performances after functional inactivation of the amygdala," <i>Behavioral Brain Research</i> , Vol. 155, pp. 223-229	
	C288	MIYAKE et al., 1977, "Purification of Human Erythropoietin," <i>J. Biol. Chem.</i> , 252(15):5558-5564.	
	C289	MOGENSEN et al., 2004, Erythropoietin improves place learning in fimbria-fornix-transsected rats and modifies the search pattern of normal rats," <i>Pharmacology, Biochemistry and Behavior</i> , Vol. 77:381-390	
	C290	MORELL et al., 1968, "Physical and Chemical Studies on Ceruloplasmin," <i>Metabolic Studies on Sialic Acid-Free Ceruloplasmin In Vivo</i> , <i>J. Biol. Chem.</i> , 243(1):155-159.	
/CMW/	C291	MUN and GOLPER, 2000, "Impaired biological activity of erythropoietin by cyanate carbamylation," <i>Blood Purif.</i> 18:13-17	

EXAMINER  
NYI-4228197v1

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO <b>10165-037-999</b>	APPLICATION NO <b>10/520,140</b>
APPLICANT <b>Brines et al.</b>			
FILING DATE <b>January 3, 2005</b>		ART UNIT <b>1647</b>	

/CMW/	C292	MURAKAMI et al., 1991, "Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family," <i>Proc. Natl. Acad. Sci. USA</i> 88(24):11349-11353	
	C293	MURRAY, 1996, <i>Harpers Illustrated Biochemistry</i> 26 <sup>th</sup> ed. pp. 524-526, McGraw-Hill Co.	
	C294	NAGAO et al., 1992, "Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor," <i>Biochem. Biophys. Res. Comm.</i> 188(2):888-897	
	C295	NAKAMURA et al., 1998, "Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients", <i>Am. J. Med. Sci.</i> 315(3):199-201	
	C296	NARANDA et al., 2002, "Activation of erythropoietin receptor through a novel extracellular binding site," <i>Endocrinology</i> 143(6):2293-2302	
	C297	NATHAN, 1994, "Studies of hybrid hematopoietic growth factor receptors," <i>Stem Cells</i> 12 (Suppl 1):27-35	
	C298	NESTLER et al., 1985, "Stimulation of rat ovarian cell steroidogenesis by high density lipoproteins modified with tetraniromethane," <i>J. Biol. Chem.</i> 260(12):7316-21	
	C299	NIMTZ and CONRADT, 1993, "Characterization of a phosphorylated oligosaccharide from erythropoietin expressed in recombinant BHK cells," <i>Glycoconj. J.</i> 10(4):259, Abstr. S.6.7	
	C300	NOGUCHI et al., 1991, "Cloning of the human erythropoietin receptor gene," <i>Blood</i> 78(10):2548-2556	
	C301	OHTA et al., 2001, "Selective glycopeptide mapping of erythropoietin by on-line high-performance liquid chromatography-electrospray ionization mass spectrometry," <i>J. Chromatography A</i> , 910:1-11	
	C302	OKADA et al., 1996, "Erythropoietin stimulates proliferation of rat-cultured gastric mucosal cells", <i>Digestion</i> 57:328-332	
	C303	OPITZ et al., 1995, "Arrhythmias and Death After Coronary Artery Occlusion in the Rat," <i>Circulation</i> , 92(2):253-261	
	C304	OPITZ et al., 1998, "Effects of reperfusion on arrhythmias and death after coronary artery occlusion in the rat: increased electrical stability independent of myocardial salvage," <i>J. Am. Coll. Cardiol.</i> 32(1): 261-267	
	C305	PAGE et al., 1996, "A sensitive human cell line based bioassay for megakaryocyte growth and development factor or thrombopoietin," <i>Cytokine</i> 8(1):66-69	
	C306	PANTOLIANO et al., 1987, "Protein engineering of subtilisin BPN': Enhanced stabilization through the introduction of two cysteines to form a disulfide bond," <i>Biochemistry</i> 26:2077-2082	
	C307	PARDRIDGE, 1998, "CNS drug design based on principles of blood-brain barrier transport." <i>J Neurochem.</i> 70:1781-92.	
	C308	PARK and HONG, 1997, "Development of an in vitro bioassay system for human thrombopoietin by constructing a recombinant murine cell line expressing human thrombopoietin receptor," <i>Mol. Cells</i> . 7(6):699-704	
	C309	PAZUR et al., 2000, "Oligosaccharides as immuno-determinants of erythropoietin for two sets of anti-carbohydrates antibodies," <i>J. Protein Chem.</i> Vol. 19(8):631-635	
	C310	PEDERSEN et al., 1995, "The interaction of beta 2-microglobulin ( $\beta$ 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m," <i>Eur. J. Immunol.</i> 25:1609-16	
	C311	PENG et al., 2000, "HPLC/ESI MS and MALDI/TOF MS analysis of microheterogeneity of the N-linked oligosaccharides of recombinant human erythropoietin," <i>Yao Xue Bao (Acta Pharmacologica Sinica)</i> 35(10):770-773 (w/ English abstract)	
	C312	PENNY and FORGET, 1991, "Genomic organization of the human erythropoietin receptor gene," <i>Genomics</i> 11(4):974-980	
	C313	PETITTO, 1979, "Early and late mechanisms of increased vascular permeability following experimental cerebral infarction," <i>J. Neuropathol Exp. Neurol.</i> 38(3):222-234	
/CMW/	C314	PFEFFER et al., 1991, Progressive ventricular remodeling in rat with myocardial infarction. <i>Am. J. Physiol.</i> 260(Pt 2): H1406-1414	

EXAMINER NYI-4228197v1	DATE CONSIDERED
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY DOCKET NO 10165-037-999	APPLICATION NO. 10/520,140
APPLICANT <b>Brines et al.</b>	
FILING DATE January 3, 2005	ART UNIT 1647

/CMW/	C315	PHYSICIANS' DESK REFERENCE, 1995, 49 <sup>th</sup> Edition (Medical Economics Data Production Company, Montvale, NJ), pp. 1765-1769	
	C316	PHYSICIANS' DESK REFERENCE, 2000 (Medical Economics Company, Inc. Montvale, NJ), pp. 519-525 and 2125-2131	
	C317	PILBEAM et al., 1993, "Comparison of the effects of various lengths of synthetic human parathyroid hormone-related peptide (hPTHrP) of malignancy on bone resorption and formation in organ culture," <i>Bone</i> 14:717-720	
	C318	PLAPP et al., 1971, "Activity of bovine pancreatic deoxyribonuclease A with modified amino groups," <i>J. Biol. Chem.</i> 246(4):939-45	
	C319	PONGER et al., 1983, "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure," <i>Diabetes</i> 32:1087-1091	
	C320	QUI et al., 1998, "Homodimerization restores biological activity to an inactive erythropoietin mutant," <i>J. Biol. Chem.</i> 273(18):11173-11176	
	C321	REMICK, 2003, "Cytokine therapeutics for the treatment of sepsis: why has nothing worked?" <i>Current Pharmaceutical Design</i> , 9:75-82	
	C322	REMY et al., 1999, "Erythropoietin receptor activation by a ligand-induced conformation change," <i>Science</i> 283:990-993	
	C323	ROBINSON et al., 1975, "Tetanus toxin. The effect of chemical modifications on toxicity, immunogenicity, and conformation," <i>J. Biol. Chem.</i> 250(18):7435-42	
	C324	ROMANOVSKY et al., 1996, "First and second phases of biphasic fever: two sequential stages of the sickness syndrome?" <i>Am. J. Physiol.</i> 271(1 pt. 2):R244-R253	
	C325	ROSENBAUM et al., 1997, "Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid," <i>Vision Res.</i> 37(24):3445-3451	
	C326	RUSH et al., 1993, "Peptide mapping and evaluation of glycopeptide microheterogeneity derived from endoprotease digestion of erythropoietin by affinity high-performance capillary electrophoresis," <i>Anal. Chem.</i> 65(14):1834-1842	
	C327	RUSH et al., 1995, "Microheterogeneity of erythropoietin carbohydrate structure," <i>Anal. Chemistry</i> , 67(8):1442-1452	
	C328	SAITO et al., 1990, "Role of neuroexcitation in development of blood-brain barrier and oedematous changes following cerebral ischaemia and traumatic brain injury," <i>Acta Neurochirurgica, Suppl.</i> 51:186-188	
	C329	SCHUSSLER et al., 1998, "Erythropoietin and obstetrical influences," <i>Zeitschrift für Geburtshilfe und Neontiologie</i> 202(2):64-68 (With English Abstract)	
	C330	SCOTT et al., 2000, "Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor," <i>Blood</i> 96(4):1588-1590	
	C331	SHIKAMA et al., 1996, "A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines," <i>Blood</i> 88(2):455-464	
	C332	SHULMAN et al., 2002, "Current drug treatment of Sepsis," <i>Hospital Pharmacist</i> 9:97-107	
	C333	SODA et al., 1984, "Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow," <i>J Ultrastruct Res.</i> 88(1):18-29	
	C334	STARKE, 1967, "Modification of protein with cyanate" <i>Methods Enzymol.</i> 11:590-594	
	C335	STENESH, J., 1989, <i>Dictionary of Biochemistry And Molecular Biology</i> , 2 <sup>nd</sup> Ed., New York, John Wiley & Sons, p. 122, p. 508	
	C336	STURM et al., 2005, "Recombinant human erythropoietin: effects on frataxin expression in vitro," <i>European J. of Clinical Investigation</i> , Vol. 35, pp. 711-717	
/CMW/	C337	SUZUKI et al., 1983, "The effects of 5-minute ischemia in Mongolian gerbils: 1. Blood-brain barrier, cerebral blood flow, and local cerebral glucose utilization changes," <i>Acta Neuropathologica (Berlin)</i> 60:207-216	

EXAMINER  
NYI-4228197v1

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ITY DOCKET NO 10165-037-999	APPLICATION NO 10/520,140
APPLICANT <b>Brines et al.</b>	
FILING DATE January 3, 2005	ART UNIT 1647

/CMW/	C338	SWEENEY et al., 1995, "Cellular mechanisms involved in brain ischemia," Can. J. Physiol. Pharmacol. Vol. 73:1525-1535
	C339	SWISS PROT ACCESSION No. P32927, October 1, 1993 (IL3 RB Human)
	C340	SYED et al., 1998, "Efficiency of signaling through cytokine receptors depends critically on receptor orientation," Nature 395:511-516
	C341	AKAHASHI, 1977, "The reactions of phenylglyoxal and related reagents with amino acids," J. Biochem., Vol. 81:395-402
	C342	TEMPLE et al., 1995, "Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis," Nephrology Dialysis Transplantation, Vol. 10:1733-1738
	C343	TEHEN et al., 1995, Doppler evaluation of severity of mitral regurgitation: relation to pulmonary venous blood flow patterns in an animal study. J. Am. Coll. Cardiol. 25(1): 264-268
	C344	TOJO et al., 1987, "Identification of erythropoietin receptors on fetal liver erythroid cells," Biochem. Biophys. Res. Commun. 148(1):443-448
	C345	URENA, 2002, "Treatment of anemia in chronic renal failure by a long-active activator of erythropoiesis," Press Medicae 31(11):505-514 (w/ English abstract)
	C346	VAN DER MEER et al., 2005, "Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction," JACC, Vol. 46(11) pp. 125-133
	C347	VANSTEENKISTE et al., 2003, "Darbepeoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia," Expert Opin. Biol. Ther. Vol. 3(3):501-508
	C348	VEZZANI et al., 1999, "Interleukin-1 $\beta$ immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: Functional evidence for enhancement of electrographic seizures," J. Neurosci. 19(12):5054-65
	C349	VEZZANI et al., 1986, "Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: Electroencephalographic, behavioral and histological assessments," J. Pharmacol. Exp. Ther. 239(1):256-263
	C350	VUKICEVIC et al., 1996, "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)," PNAS USA 93:9021-9026
	C351	WAUBEN-PENRIS et al., 1988, "The release of iron by Sertoli cells in culture," Biol. Reprod. 38:1105-1113
	C352	WELLS, 1990, "Additivity of mutational effects in proteins," Biochemistry 29(37):8509-8517
	C353	WEN et al., 1994, "Erythropoietin structure-function relationships," J. Biol. Chem. 269(36):22839-22846
	C354	WIDNESS et al., 1995, "Erythropoietin transplacental passage-Review of animal studies," J. Perinat. Med. 23: 61-70
	C355	WILLIAMSON et al., 1993, "Protein and lipid kinase activation cascades in interleukin-2 receptor signalling," Semin. Immunol. 5(5):337-344
	C356	WINKELMANN et al., 1990, "The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p," Blood 76(1):24-30
	C357	WIT et al., 1992, "Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction," Circulation 85 Suppl. 1:1-32-1-42
	C358	WOJCHOWSKI and CASLAKE, 1989, "Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligands," Blood, Vol. 74(3):952-958
↓	C359	WOLF et al., 1997, "Erythropoietin administration increases production and reactivity of platelets in dogs," Thromb. Haemost. 78:1505-1509
/CMW/	C360	WU and PARDRIDGE, 1996, "Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system," J Pharmacol Exp Ther. 279(1):77-83

EXAMINER  
NYI-4228197v1

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY DOCKET NO.	APPLICATION NO
10165-037-999	10/520,140
APPLICANT	
Brines et al.	
FILING DATE	ART UNIT
January 3, 2005	1647

/CMW/	C361	XIAO et al., 1998, "Fibrinogen deficiency is compatible with the development of atherosclerosis in mice," J. Clin Invest. 101(5):1184-1194	
	C362	YAMAMURA et al., 1992, "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor," EMBO J. 11(13):4909-4915	
	C363	YANG et al., 1994, "Reperfusion-induced injury to the blood-brain barrier after middle-cerebral artery occlusion in rats," Stroke, Vol. 25(8):1658-1665	
	C364	YET et al., 1993, "The extracytoplasmic domain of the erythropoietin receptor forms a monomeric complex with erythropoietin," Blood 82(6):1713-1719	
	C365	YOSHIMURA et al., 1995, "A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors," EMBO J. 14(12):2816-2826	
	C366	YOSHIMURA et al., 1996, "Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway," EMBO J. 15(5):1055-1063	
	C367	YOSHIMURA et al., 1996, "Physician Education: The Erythropoietin Receptor and Signal Transduction," Oncologist 1(5):337-339	
	C368	ZENG, 1991, "Lysine modification of metallothionein by carbamylation and guanidination," Methods Enzymol. 205:433-437	
	C369	ZHANG et al., 2006, "Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms," J. Neurosci. Res. 83:1241-51	
	C370	ZHU et al., 2002, "Detecting and responding to hypoxia," Nephrol. Dial. Transplant. 17 Suppl 1:3-7	
	C371	Office Action, Application No. 09/547,220, date mailed: May 8, 2002	
	C372	Office Action, Application No. 09/547,220, date mailed: June 13, 2002	
	C373	Office Action, Application No. 09/547,220, date mailed: October 22, 2002	
	C374	Office Action, Application No. 09/547,220, date mailed: January 28, 2003	
	C375	Office Action, Application No. 09/547,220, date mailed: December 2, 2003	
	C376	Office Action, Application No. 09/547,220, date mailed: September 22, 2004	
	C377	Office Action, Application No. 09/547,220, date mailed: June 6, 2005	
	C378	Office Action, Application No. 09/547,220, date mailed: February 22, 2006	
	C379	Office Action, Application No. 09/547,220, date mailed: August 31, 2006	
	C380	Notice of Abandonment, Application No. 09/547,220, date mailed: June 26, 2007	
	C381	Office Action, Application No. 09/716,960, date mailed: August 26, 2002	
	C382	Office Action, Application No. 09/716,960, date mailed: July 25, 2003	
	C383	Office Action, Application No. 09/716,960, date mailed: March 8, 2004	
	C384	Office Action, Application No. 09/716,960, date mailed: September 16, 2004	
	C385	Office Action, Application No. 09/716,960, date mailed: January 19, 2005	
	C386	Office Action, Application No. 09/716,960, date mailed: May 8, 2006	
	C387	Office Action, Application No. 09/716,960, date mailed: February 1, 2007	
	C388	Office Action, Application No. 09/716,960, date mailed: October 16, 2007	
/CMW/	C389	Office Action, Application No. 09/716,960, date mailed: December 6, 2007	

EXAMINER NYL42281971	DATE CONSIDERED
-------------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		ATTY DOCKET NO <b>10165-037-999</b>	APPLICATION NO <b>10/520,140</b>
APPLICANT <b>Brines et al.</b>			
FILING DATE <b>January 3, 2005</b>		ART UNIT <b>1647</b>	

/CMW/	C390	Notice of Allowance, Application No. 09/716,960, date mailed: February 21, 2008	
	C391	Office Action, Application No. 09/717,057, date mailed: May 17, 2002	
	C392	Office Action, Application No. 09/717,057, date mailed: November 1, 2002	
	C393	Office Action, Application No. 09/717,057, date mailed: July 15, 2003	
	C394	Office Action, Application No. 09/717,057, date mailed: April 5, 2004	
	C395	Office Action, Application No. 09/717,057, date mailed: October 26, 2004	
	C396	Office Action, Application No. 09/717,057, date mailed: April 5, 2005	
	C397	Office Action, Application No. 09/717,057, date mailed: January 9, 2006	
	C398	Office Action, Application No. 09/717,057, date mailed: October 10, 2006	
	C399	Notice of Allowance, Application No. 09/717,057, date mailed: May 18, 2007	
	C400	Office Action, Application No. 09/717,053, date mailed: May 13, 2002	
	C401	Office Action, Application No. 09/717,053, date mailed: July 16, 2002	
	C402	Office Action, Application No. 09/717,053, date mailed: April 9, 2003	
	C403	Office Action, Application No. 09/717,053, date mailed: October 15, 2003	
	C404	Office Action, Application No. 09/717,053, date mailed: April 20, 2004	
	C405	Office Action, Application No. 09/717,053, date mailed: May 3, 2005	
	C406	Office Action, Application No. 09/717,053, date mailed: January 20, 2006	
	C407	Office Action, Application No. 09/717,053, date mailed: October 24, 2006	
	C408	Notice of Allowance, Application No. 09/717,053, date mailed: April 26, 2007	
	C409	Office Action, Application No. 09/753,132, date mailed: January 25, 2002	
	C410	Office Action, Application No. 10/185,841, date mailed: April 28, 2005	
	C411	Office Action, Application No. 10/185,841, date mailed: January 18, 2006	
	C412	Office Action, Application No. 10/185,841, date mailed: October 5, 2006	
	C413	Office Action, Application No. 10/185,841, date mailed: June 27, 2007	
	C414	Interview Summary, Application No. 10/185,841, date mailed: February 27, 2008	
	C415	Office Action, Application No. 10/185,841, date mailed: January 9, 2009	
	C416	Notice of Allowance, Application No. 10/185,841, date mailed: April 10, 2009	
	C417	Notice of Allowance, Application No. 10/185,841, date mailed: October 22, 2009	
	C418	Office Action, Application No. 10/188,905, date mailed: August 22, 2005	
	C419	Office Action, Application No. 10/188,905, date mailed: March 21, 2006	
	C420	Office Action, Application No. 10/188,905, date mailed: December 7, 2006	
	C421	Office Action, Application No. 10/188,905, date mailed: May 28, 2008 (Interview Summary 5/21/08)	
/CMW/	C422	Office Action, Application No. 10/188,905, date mailed: October 15, 2008	

EXAMINER NY14228197v1	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
 (Use several sheets if necessary)

ATTY DOCKET NO. 10165-037-999	APPLICATION NO. 10/520,140
APPLICANT <b>Brines et al.</b>	
FILING DATE January 3, 2005	ART UNIT 1647

/CMW/	C423	Office Action, Application No. 10/188,905, date mailed: February 12, 2009 (Interview Summary 2/04/09)	
	C424	Office Action, Application No. 10/351,640, date mailed: December 13, 2005	
	C425	Office Action, Application No. 10/351,640, date mailed: August 28, 2006	
	C426	Office Action, Application No. 10/351,640, date mailed: June 5, 2007	
	C427	Office Action, Application No. 10/351,640, date mailed: September 19, 2008	
	C428	Office Action, Application No. 10/612,665 date mailed: June 20, 2006	
	C429	Office Action, Application No. 10/612,665 date mailed: February 23, 2007	
	C430	Office Action, Application No. 10/612,665 date mailed: December 31, 2007	
	C431	Office Action, Application No. 10/612,665 date mailed: December 11, 2008	
	C432	Office Action, Application No. 11/880,275, date mailed: May 22, 2009	
	C433	Office Action, Application No. 11/881,759, date mailed: December 12, 2007	
	C434	Office Action, Application No. 11/881,759, date mailed: July 18, 2008	
	C435	Office Action, Application No. 11/881,759, date mailed: September 24, 2008	
	C436	Office Action, Application No. 11/881,759, date mailed: July 21, 2009	
	C437	Office Action, Application No. 11/893,294, date mailed: June 16, 2008	
	C438	Office Action, Application No. 11/893,294, date mailed: October 10, 2008	
	C439	Office Action, Application No. 11/893,294, date mailed: February 2, 2009	
	C440	Office Action, Application No. 10/188,905, date mailed: November 12, 2009	
	C441	Ghezzi et al., 2004, "Erythropoietin as an antiapoptotic, tissue protective cytokine"	
	C442	International Search Report for PCT/US00/10019, mailed August 30, 2000	
	C443	LINDAHL, 1980, "The contributions of erythropoietic and nonerythropoietic haem turnover to the early labelled peak of endogenous CO formation in man," Scand. J. Haematol. Apr 24 (4): 271-80	
	C444	SALINSKA et al., 2005, "The role of excitotoxicity in neurodegeneration." Folia Neuropathol., 43(4):322-339	
	C445	SEGURA-AGUILAR et al., 2004, "Neurotoxins and neurotoxic species implicated in neurodegeneration." Neurotox. Res., 6(7,8):615-630	
	C446	WANG et al, 2005, "Kainic acid-mediated excitotoxicity as a model for neurodegeneration." Molec. Neurobiol., 31(1-3): 3-16	
	C447	TRIST, 2000, "Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications." Pharmaceutica Acta Helveticae, 74:221-229	
	C448	Written Opinion for PCT/US00/10019, mailed August 16, 2001	
↓	C449	Office Action, Application No. 10/351,640, date mailed: July 7, 2009	
/CMW/	C450	Office Action, Application No. 11 893,294, date mailed: August 13, 2009	

EXAMINER NYI-422819761	/Cherie M. Woodward/	DATE CONSIDERED	03/21/2010
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			